What they were paid
Black Diamond Therapeutics Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $48,000 | $0 | $57,030 | $0 | $105,030 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Black Diamond Therapeutics, Inc. DEF 14A filed April 29, 2026, accession 0001104659-26-051474, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025Black Diamond Therapeutics pays directors a $40,000 cash retainer and $57,030 in Options.
Committees
FY2025 · as the proxy prints themNominating/Governance (Chair)
The rest of the Black Diamond Therapeutics board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Ali Behbahani | Independent Director | $114,530 |
| Garry E. Menzel | Independent Director | $117,030 |
| Mark A. Velleca | Chair of the Board | $0 |
| Prakash Raman | Independent Director | $108,530 |
| Samarth Kulkarni | Lead Independent Director | $126,030 |
| Shannon Campbell | Independent Director | $108,030 |
The full Black Diamond Therapeutics compensation record
free company briefThis page is one director within Black Diamond Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat